{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:55:38Z","timestamp":1790474138099,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["1062-B33"],"award-info":[{"award-number":["1062-B33"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["KH130356"],"award-info":[{"award-number":["KH130356"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["I3522"],"award-info":[{"award-number":["I3522"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["KKP126790"],"award-info":[{"award-number":["KKP126790"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["I4677"],"award-info":[{"award-number":["I4677"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["2020-1.1.6-J\\u00D6V\\u0150"],"award-info":[{"award-number":["2020-1.1.6-J\\u00D6V\\u0150"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["I3977"],"award-info":[{"award-number":["I3977"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.canlet.2023.216395","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:00:57Z","timestamp":1695002457000},"page":"216395","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo"],"prefix":"10.1016","volume":"574","author":[{"given":"Karin","family":"Schelch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0687-5778","authenticated-orcid":false,"given":"Dominik","family":"Emminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Zitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-6958","authenticated-orcid":false,"given":"Thomas G.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-1398","authenticated-orcid":false,"given":"Verena","family":"Kopatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-3053","authenticated-orcid":false,"given":"Sebastian","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4316-5377","authenticated-orcid":false,"given":"Alexander","family":"Ries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5262-1146","authenticated-orcid":false,"given":"Alessia","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6401-8646","authenticated-orcid":false,"given":"Petra","family":"Heffeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir A.","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Hoetzenecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-5223","authenticated-orcid":false,"given":"Glen","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216395_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00428-021-03031-7","article-title":"Pleural mesothelioma classification update","volume":"478","author":"Beasley","year":"2021","journal-title":"Virchows Arch."},{"key":"10.1016\/j.canlet.2023.216395_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164194","article-title":"Epidemiology and clinical aspects of malignant pleural mesothelioma","volume":"13","author":"Brims","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216395_bib3","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.thorsurg.2020.08.005","article-title":"The molecular basis of malignant pleural mesothelioma","volume":"30","author":"Wadowski","year":"2020","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.canlet.2023.216395_bib4","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2023.216395_bib6","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the treatment of malignant pleural mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2023.216395_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","article-title":"First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743","volume":"33","author":"Peters","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/OP.21.00426","article-title":"Management of advanced pleural mesothelioma-at the crossroads","volume":"18","author":"Nowak","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.canlet.2023.216395_bib9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fcell.2019.00221","article-title":"Why Be one protein when you can affect many? The multiple roles of YB-1 in lung cancer and mesothelioma","volume":"7","author":"Johnson","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2023.216395_bib10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2017.10.016","article-title":"Dysregulated expression of the MicroRNA miR-137 and its target YBX1 contribute to the invasive characteristics of malignant pleural mesothelioma","volume":"13","author":"Johnson","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082285","article-title":"YB-1 knockdown inhibits the proliferation of mesothelioma cells through multiple mechanisms","volume":"12","author":"Johnson","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216395_bib12","article-title":"YB-1 regulates mesothelioma cell migration via Snail but not EGFR, MMP1, EPHA5 or PARK2","author":"Schelch","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib13","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948375","article-title":"Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis","volume":"20","author":"El-Naggar","year":"2019","journal-title":"EMBO Rep."},{"key":"10.1016\/j.canlet.2023.216395_bib14","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","article-title":"Telomerase reverse transcriptase promoter mutations identify a genomically defined and highly aggressive human pleural mesothelioma subgroup","volume":"26","author":"Pirker","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216395_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/rccm.201404-0658OC","article-title":"Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy","volume":"190","author":"Schelch","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.canlet.2023.216395_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1878-0261.12150","article-title":"A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma","volume":"12","author":"Schelch","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib17","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/JTO.0b013e31820e1a25","article-title":"Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy","volume":"6","author":"Hoda","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.canlet.2023.216395_bib19","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1134\/S0006297911130049","article-title":"Y-box-binding protein 1 (YB-1) and its functions","volume":"76","author":"Eliseeva","year":"2011","journal-title":"Biochemistry (Mosc.)"},{"key":"10.1016\/j.canlet.2023.216395_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110073","article-title":"A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance","volume":"85","author":"Alkrekshi","year":"2021","journal-title":"Cell. Signal."},{"key":"10.1016\/j.canlet.2023.216395_bib21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2174\/1568009621666210831125001","article-title":"Potential therapeutic strategies for targeting Y-box-binding protein 1 in cancers","volume":"21","author":"Yang","year":"2021","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.canlet.2023.216395_bib22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"van Zandwijk","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib23","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","article-title":"Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"109","author":"Gojo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216395_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CMR.0b013e328307c248","article-title":"Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma","volume":"18","author":"Hauschild","year":"2008","journal-title":"Melanoma Res."},{"key":"10.1016\/j.canlet.2023.216395_bib25","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2011.38.9411","article-title":"Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy","volume":"30","author":"Witta","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-11-0214","article-title":"Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer","volume":"1","author":"Juergens","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2023.216395_bib27","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2023.216395_bib28","first-page":"116","article-title":"Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells","volume":"55","author":"Maiti","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib29","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1158\/2326-6066.CIR-21-0170","article-title":"Entinostat decreases immune suppression to promote antitumor responses in a HER2+ breast tumor microenvironment","volume":"10","author":"Sidiropoulos","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2023.216395_bib30","first-page":"131","article-title":"Entinostat induces antitumor immune responses through immune editing of tumor neoantigens","author":"Truong","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2023.216395_bib31","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ijrobp.2021.06.021","article-title":"Targeting the Y-box binding protein-1 Axis to overcome radiochemotherapy resistance in solid tumors","volume":"111","author":"Lettau","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2023.216395_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00432-002-0386-6","article-title":"Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer","volume":"128","author":"Yahata","year":"2002","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216395_bib33","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/j.1349-7006.2011.01948.x","article-title":"An integrative approach to identify YB-1-interacting proteins required for cisplatin resistance in MCF7 and MDA-MB-231 breast cancer cells","volume":"102","author":"Garand","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2023.216395_bib34","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.biocel.2008.04.011","article-title":"The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures","volume":"40","author":"Guay","year":"2008","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2023.216395_bib35","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1349-7006.2004.tb03214.x","article-title":"Targeted disruption of one allele of the Y-box binding protein-1 (YB-1) gene in mouse embryonic stem cells and increased sensitivity to cisplatin and mitomycin C","volume":"95","author":"Shibahara","year":"2004","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2023.216395_bib36","first-page":"4224","article-title":"Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light","volume":"56","author":"Ohga","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2023.216395_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114971","article-title":"MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells","volume":"395","author":"Liu","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216395_bib38","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.canlet.2017.10.023","article-title":"Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1","volume":"414","author":"Huang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2023.216395_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nm0497-447","article-title":"Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression","volume":"3","author":"Bargou","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216395_bib40","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1158\/1535-7163.MCT-17-1240","article-title":"Induction of thioredoxin-interacting protein by a histone deacetylase inhibitor, entinostat, is associated with DNA damage and apoptosis in esophageal adenocarcinoma","volume":"17","author":"Feingold","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2023.216395_bib41","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-17-0443","article-title":"Overcoming resistance to DNA-targeted agents by epigenetic activation of schlafen 11 (SLFN11) expression with class I histone deacetylase inhibitors","volume":"24","author":"Tang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216395_bib42","doi-asserted-by":"crossref","first-page":"22400","DOI":"10.1002\/jcp.28805","article-title":"Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K\/Akt\/mTOR pathway","volume":"234","author":"Ma","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2023.216395_bib43","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4149\/304_150806N433","article-title":"Reversal of cisplatin resistance by inhibiting PI3K\/Akt signal pathway in human lung cancer cells","volume":"63","author":"Zhang","year":"2016","journal-title":"Neoplasma"},{"key":"10.1016\/j.canlet.2023.216395_bib44","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbrc.2010.03.029","article-title":"Role of the Akt\/mTOR survival pathway in cisplatin resistance in ovarian cancer cells","volume":"394","author":"Peng","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2023.216395_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12964-020-00544-7","article-title":"Merlin regulates signaling events at the nexus of development and cancer","volume":"18","author":"Mota","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2023.216395_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2023.216395_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008639","article-title":"Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship","volume":"6","author":"Shapiro","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2023.216395_bib48","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2023.216395_bib49","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","article-title":"Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition","volume":"80","author":"Srinivasan","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2023.216395_bib50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/1078-0432.CCR-17-1172","article-title":"Comprehensive pharmacogenomic profiling of malignant pleural mesothelioma identifies a subgroup sensitive to FGFR inhibition","volume":"24","author":"Quispel-Janssen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216395_bib51","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1126\/science.1194472","article-title":"Frequent mutation of BAP1 in metastasizing uveal melanomas","volume":"330","author":"Harbour","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.canlet.2023.216395_bib52","doi-asserted-by":"crossref","first-page":"13757","DOI":"10.18632\/oncotarget.3765","article-title":"Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors","volume":"6","author":"Sacco","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2023.216395_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax1738","article-title":"BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers","volume":"5","author":"Kuznetsov","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2023.216395_bib54","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523003464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523003464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:05:31Z","timestamp":1777550731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523003464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":54,"alternative-id":["S0304383523003464"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216395","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216395","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216395"}}